Efmirenpase alfa clinical trials
Also written INZ-701.
How each study uses efmirenpase alfa is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
8 studies that test it; most in 2023 (2)
| Year | Studies |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 2 |
| 2025 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 8 · Other 0
Studies
Open first, then newest update. How each study uses efmirenpase alfa is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 8
- Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 DeficiencyCompletedPhase 1/2Inozyme PharmaNCT04686175Written as INZ-701
- ADAPT Study: Long-term Safety Study of INZ-701 in Patients With ENPP1 Deficiency and ABCC6 DeficiencyTerminatedPhase 2Inozyme PharmaNCT06462547Written as INZ-701
- The ENERGY Study: Evaluation of Safety and Tolerability of INZ-701 in Infants With ENPP1 Deficiency or ABCC6 DeficiencyTerminatedPhase 1Inozyme PharmaNCT05734196Written as INZ-701
- Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ABCC6 Deficiency Causing PXECompletedPhase 1/2Inozyme PharmaNCT05030831Written as INZ-701
- The ENERGY 3 Study: Evaluation of Efficacy and Safety of INZ-701 in Children With ENPP1 DeficiencyTerminatedPhase 3Inozyme PharmaNCT06046820Written as INZ-701
- ENERGY 2: Evaluation of the Efficacy and Safety of INZ-701 in Infants With ENPP1 DeficiencyTerminatedPhase 3Inozyme PharmaNCT07473973Written as INZ-701
- SEAPORT 1: Study of INZ-701 in Adults With Hemodialysis-Dependent End-Stage Kidney DiseaseCompletedPhase 1Inozyme PharmaNCT06283589Written as INZ-701
- The ENABLE Study: Safety and Efficacy Study of INZ-701 in Patients With ENPP1 DeficiencyWithdrawnPhase 2Inozyme PharmaNCT06739980Written as INZ-701
Codes
What other systems call efmirenpase alfa · ClinicalTrials.gg INT015747
- UNII (FDA) 8ZH1P9LXW1EFMIRENPASE ALFAOne source FDA
- NCI Thesaurus C224731Efmirenpase AlfaOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 8ZH1P9LXW1 | EFMIRENPASE ALFA | One source FDA |
| NCI Thesaurus | C224731 | Efmirenpase Alfa | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.